Schrodinger reported a mixed fourth quarter with total revenue declining slightly by 1.2% due to a transition in software revenue recognition, though the company achieved a net income of $32.5 million compared to a loss in the prior year. The company is accelerating its shift to a hosted software model to improve revenue predictability by 2028.

Schrödinger delivered strong second-quarter results, with total revenue reaching $54.8 million, a 16% increase from the prior year. Software revenue grew by 15% to $40.5 million, and drug discovery revenue increased by 19% to $14.2 million. Despite a net loss of $43.2 million, the company's operating expenses decreased, and it reaffirmed its full-year revenue guidance while lowering operating expense projections. Key clinical milestones were also achieved, with encouraging initial data for SGR-1505 and expected data for SGR-3515 and SGR-2921 in Q4 2025.

Schrödinger reported strong performance in the first quarter of 2025, with total revenue increasing 63% year-over-year to $59.6 million, driven by significant growth in both software and drug discovery segments. The company reported a GAAP net loss of $59.8 million and a non-GAAP net loss of $46.7 million for the quarter.

Schrödinger delivered a strong performance in Q4 2024, with total revenue reaching $88.3 million, a 19.1% increase year-over-year, driven by robust software revenue growth of 16.0% to $79.7 million and a significant 58% increase in drug discovery revenue to $8.7 million. Despite the revenue growth, the company reported a net loss of $40.2 million for the quarter.

Schrödinger reported a decrease in total revenue for the third quarter of 2024, while software revenue increased. The company announced a multi-target research and licensing collaboration with Novartis, receiving $150 million upfront. Updated financial guidance for 2024 was provided, with increased confidence in software revenue growth.

Schrödinger, Inc. announced strong financial results for the second quarter of 2024, featuring a 35% increase in total revenue to $47.3 million. Software revenue grew by 21% to $35.4 million, and drug discovery revenue more than doubled to $11.9 million. The company is progressing its proprietary therapeutics pipeline, with initial clinical data expected from lead programs in 2025.

Schrödinger reported a decrease in total revenue due to a large collaboration milestone payment in the previous year, while software revenue increased. The company announced FDA clearance of its IND application for SGR-3515 and expects initial data readouts for SGR-1505 and SGR-2921 in late 2024 or 2025.

Schrödinger's Q4 2023 total revenue increased by 30.4% to $74.1 million, with software revenue up 43.6% to $68.7 million. The company's net loss for the quarter was $30.7 million. The company expects software revenue growth of 6% to 13% in 2024.

Schrödinger reported a strong third quarter with total revenue of $42.6 million, a 15.1% increase compared to the third quarter of 2022. The company saw growth in both software and drug discovery revenue. They updated their financial guidance for 2023.

Schrödinger reported a strong first quarter with total revenue of $64.8 million, a 33% increase compared to Q1 2022. The company's drug discovery collaborations advanced, and they initiated Phase 1 studies. A $147.3 million distribution from the sale of Nimbus’s TYK2 inhibitor to Takeda significantly strengthened their cash position.

Schrödinger's Q4 2022 saw a 23% increase in total revenue to $56.8 million, with software revenue up 24% to $47.8 million and drug discovery revenue at $9.0 million. The company reported a net loss of $27.2 million for the quarter. They anticipate continued revenue growth and reduced cash burn in 2023.

Schrödinger reported a strong third quarter with software revenue in line with expectations and strong drug discovery revenue. The company initiated a Phase 1 study for its MALT1 program and is preparing to present new preclinical data from its CDC7 program. The company's total revenue increased by 24% compared to Q3 2021.

Schrödinger reported strong second-quarter results with total revenue reaching $38.5 million, a 29% increase year-over-year. Software and drug discovery segments contributed to this growth, and the company's cash position remained strong. The investigational new drug application for the MALT1 inhibitor, SGR-1505, was cleared for Phase 1 clinical development.

Schrödinger reported a strong first quarter in 2022, with a 51% increase in total revenue to $48.7 million compared to the first quarter of 2021. Software revenue increased by 26% to $33.1 million, and drug discovery revenue saw a substantial increase of 169% to $15.6 million. The company is progressing with its internal pipeline, with an IND submission for SGR-1505 on track for the first half of 2022.

Schrödinger reported a strong fourth quarter, with software revenue increasing by 55% compared to the fourth quarter of 2020. The company's total revenue for the quarter was $46.2 million, a 40% increase year-over-year. Schrödinger also provided its financial outlook for 2022 and outlined key strategic goals for 2022-2023.

Schrödinger reported a total revenue of $29.9 million for Q3 2021, a 16% increase compared to Q3 2020. Software revenue was $24.3 million, and drug discovery revenue was $5.6 million. The company's net loss was $35.0 million, driven by adjustments to the fair value of the company’s equity investments as well as planned investments to advance the company’s growth strategy.

Schrödinger reported a strong second quarter with a 29% increase in total revenue, driven by growth in both software and drug discovery segments. The company highlighted progress in its internal drug discovery pipeline and a new oncology collaboration with Zai Lab.

Schrödinger reported a strong first quarter with a 23% increase in total revenue, driven by significant growth in drug discovery revenue and continued adoption of its software platform. The company also expanded its collaboration with AstraZeneca and formed a new partnership with NVIDIA.

Schrödinger reported a 28% increase in total revenue for Q4 2020, driven by strong software revenue growth and contributions from a strategic collaboration with Bristol Myers Squibb. The company ended the year with a solid financial position, enabling continued investment in its computational platform and internal pipeline.

Schrödinger, Inc. announced financial results for the second quarter ended June 30, 2020, with total revenue of $23.1 million, a 21% increase compared to the second quarter of 2019. The company saw significant growth in its software business and advanced its drug discovery programs.

Schrödinger reported a 26% year-over-year increase in total revenue, reaching $26.2 million for the first quarter of 2020. Software revenue grew by 28% to $23.8 million. The company's net loss was $13.8 million, and they ended the quarter with $288.8 million in cash, cash equivalents, and marketable securities. The company completed its IPO, raising $209.6 million in net proceeds.